Darzalex Setback In NHL Raises Stakes For First-Line Myeloma Approval

Cancer cell
Janssen/Genmab's Darzalex suffers disappointing setback in Phase II NHL studies • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from R&D